<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059875</url>
  </required_header>
  <id_info>
    <org_study_id>GYNECO ONCOGER</org_study_id>
    <nct_id>NCT03059875</nct_id>
  </id_info>
  <brief_title>Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)</brief_title>
  <official_title>Place of Comprehensive Geriatric Assessment (CGA) in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter): Comparison Between CGA Before Surgery (Strategy A) vs. After Surgery (Strategy B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      The risk of diagnosis of cancer increases with age, especially breast cancer in elderly
      women. Elderly population is heterogeneous, regarding physiological reserves, comorbidities,
      disability and geriatric conditions. Comprehensive geriatric assessment (CGA) is a
      multidimensional approach to determine geriatric profile, in helping the therapeutic
      strategy. In-patients with diagnosis of cancer are screened with the FOG (oncology geriatric
      filter), to identify vulnerable subjects who may benefit from CGA. This scale of ten
      questions includes geriatric domains such as functional status, nutrition, mood, cognitive
      abilities and comorbidities. In elderly patients with breast cancer considered as fit
      (FOG=0), CGA is not necessary before adjuvant treatment. In vulnerable patients (FOG ≤ 1 and
      &lt; 3), CGA is held in routine to discuss the adjuvant therapy feasibility. Patients with FOG ≥
      4 underwent CGA if palliative care is considered.

      Patients in the intermediate group (FOG 1-3) are randomized to determine time of CGA, before
      or after surgery.

      The aims of this study are to assess the outcomes regarding the time of CGA, in elderly
      female patients with breast cancer management, and to define the optimal place of CGA in care
      pathway.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare Comprehensive Geriatric Assessment before the surgery and Comprehensive Geriatric Assessment after the surgery</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients</measure>
    <time_frame>5 years</time_frame>
    <description>Questionnary EORTC QLQ - BR33</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with their management</measure>
    <time_frame>5 years</time_frame>
    <description>Questionnary REPERES 60 - Consumer Satisfaction Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare proportions of patients who received adjuvant chemotherapy and / or radiation standard</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare time to take care of Comprehensive Geriatric Assessment before the surgery and Comprehensive Geriatric Assessment after the surgery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the proportions of patients receiving adjuvant therapy, including complete hormone therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Surgery</condition>
  <condition>75 Years Old and More</condition>
  <condition>Female Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Strategy A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comprehensive Geriatric Assessment before the surgery of breast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comprehensive Geriatric Assessment after the surgery of breast</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical consultation for a Standardized Geriatric Evaluation</intervention_name>
    <arm_group_label>Strategy A</arm_group_label>
    <arm_group_label>Strategy B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First breast cancer localized, indication of surgery

          -  Onco-geriatric filter (FOG) &gt;= 1 ou &lt; 4

        Exclusion Criteria:

          -  Male, less of 75 years old

          -  Contraindication of surgery

          -  Breast cancer with metastasis

          -  Onco-geriatric filter (FOG) = 0 or 4
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon SV VALERO, doctor</last_name>
    <phone>05.49.44.41.70</phone>
    <email>simon.valero@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie EF FAVARD, clinical research associate</last_name>
    <phone>05.49.44.34.41</phone>
    <email>emilie.favard@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Center</name>
      <address>
        <city>Angouleme</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis DT TARIEL, Doctor</last_name>
      <phone>05.45.24.40.67</phone>
      <email>denis.tariel@ch-angouleme.fr</email>
    </contact>
    <investigator>
      <last_name>Céline CB BAUDEMONT, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélie MS SARROU, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline CJ JARRY, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis DT TARIEL, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital center</name>
      <address>
        <city>Bressuire</city>
        <zip>79302</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal PV VILLEMONTEIX, Doctor</last_name>
      <phone>05.49.68.30.01</phone>
      <email>villemonteix.pascal@chnds.fr</email>
    </contact>
    <investigator>
      <last_name>Bénédicte BK KARABETSOS, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal PV VILLEMONTEIX, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Center</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick YT THIROUARD, Doctor</last_name>
      <phone>05.46.45.52.19</phone>
      <email>yannick.thirouard@ch-larochelle.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Sébastien JA AUCOUTURIER, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno BG GROSSIN, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle ID DRAPIER-OUVRY, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick YT THIROUARD, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital center</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire CD DEKINDT, Doctor</last_name>
      <phone>05.49.78.34.57</phone>
      <email>claire.dekindt@ch-niort.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine SK KHALIFA, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit BP PUSNIAK, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire CD DEKINDT, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon SV VALERO, Doctor</last_name>
      <phone>05.49.44.41.70</phone>
      <email>simon.valero@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie EF FAVARD, Clinical research associate</last_name>
      <phone>05.49.44.34.41</phone>
      <email>emilie.favard@chu-poitiers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cédric CN NADEAU, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier XF FRITEL, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas NG GUILHEN, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon SV VALERO, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital center</name>
      <address>
        <city>Saintes</city>
        <zip>17108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucile LB BRETHEAU, Doctor</last_name>
      <phone>05.46.95.15.06</phone>
      <email>l.bretheau@ch-saintonge.fr</email>
    </contact>
    <investigator>
      <last_name>Sandra SC SCHREINER, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie SB BOULANGER, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique DC CAMBON, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucile LB BRETHEAU, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breastcancer</keyword>
  <keyword>Standardized Geriatric Evaluation</keyword>
  <keyword>Onco-Geriatric Filter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

